Cited by 2,190Neuroinflammation and Neurodegeneration MechanismsNeurological Disease Mechanisms and TreatmentsInflammasome and immune disorders

Differential Roles of M1 and M2 Microglia in Neurodegenerative Diseases

Tang, Yu, Le, Weidong·2016·Molecular Neurobiology

Abstract

One of the most striking hallmarks shared by various neurodegenerative diseases, including Parkinson's disease, Alzheimer's disease (AD), and amyotrophic lateral sclerosis, is microglia-mediated neuroinflammation. Increasing evidence indicates that microglial activation in the central nervous system is heterogeneous, which can be categorized into two opposite types: M1 phenotype and M2 phenotype. Depending on the phenotypes activated, microglia can produce either cytotoxic or neuroprotective effects. In this review, we focus on the potential role of M1 and M2 microglia and the dynamic changes of M1/M2 phenotypes that are critically associated with the neurodegenerative diseases. Generally, M1 microglia predominate at the injury site at the end stage of disease, when the immunoresolution and repair process of M2 microglia are dampened. This phenotype transformation is very complicated in AD due to the phagocytosis of regionally distributed β-amyloid (Aβ) plaque and tangles that are released into the extracellular space. The endogenous stimuli including aggregated α-synuclein, mutated superoxide dismutase, Aβ, and tau oligomers exist in the milieu that may persistently activate M1 pro-inflammatory responses and finally lead to irreversible neuron loss. The changes of microglial phenotypes depend on the disease stages and severity; mastering the stage-specific switching of M1/M2 phenotypes within appropriate time windows may provide better therapeutic benefit.

Integrity signals

Registry

Crossref · 10.1007/s12035-014-9070-5

Cites

159 of 159 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Intranasal administration of Semax over a 7-day treatment course resulted in a 25% decrease of infarct volume in the prefrontal cortex and cognitive function recovery over the long term.

    “Intranasal administration of Semax over the 7-day treatment course resulted in a 25% decrease of infarct volume in the prefrontal cortex and cognitive function recovery over the long term [45,81].”
  • Activated microglia and an aberrant proinflammatory phenotype contribute to neuronal damage and synaptic dysfunction by releasing cytokines, reactive oxygen species, and other inflammatory mediators, which perpetuate neurodegeneration and exacerbate Alzheimer's disease progression.

    “activated microglia (De Strooper and Karran, 2016) and aberrant proinflammatory phenotype contribute to neuronal damage and synaptic dysfunction by releasing cytokines, reactive oxygen species, and other inflammatory mediators, which could perpetuate neurodegeneration and exacerbate the progression of AD (Tang and Le, 2016).”
  • Microglia adopt two distinct activation phenotypes, composed of a proinflammatory and neurotoxic classical activation (M1) phenotype by exposure to LPS and IFNγ and an anti-inflammatory and neuroprotective alternative activation (M2) phenotype following treatment with IL-4 and IL-13.

    “Microglia adopt two distinct activation phenotypes, composed of a proinflammatory and neurotoxic”
  • The first immune response to an insult in the nervous system is the activation of microglial cells of the M2 phenotype, which is involved in anti-inflammatory mechanisms for defense and injury repair.

    “The first immune response to an insult in the nervous system is the activation of microglial cells of the M2 phenotype, which is involved in anti-inflammatory mechanisms for defense and injury repair [132].”
  • M2 microglia can release anti-inflammatory cytokines including IL-4, IL-13, IL-10, TGF-β and neurotrophic factors such as IGF-1 to assist inflammation resolution and promote neuron survival.

    “These cells can release anti-inflammatory cytokines including IL-4, IL-13, IL-10, TGF-β and neurotrophic factors, such as insulin-like growth factor 1 (IGF-1) to assist inflammation resolution and promote neuron survival (Suh et al., 2013; Tang and Le, 2016).”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Tang, Y., & Le, W.
Affiliations
  • Shanghai Jiao Tong University (CN)
  • Dalian Medical University (CN)
Corresponding author
Le, Weidong
Venue
Molecular Neurobiology
Published
2015-01-20
Volume
53
Issue
2
Pages
1181-1194
ISSN
  • 0893-7648 (ISSN-L)
  • 1559-1182
OpenAlex
W2069893872
Cited by
2,190
References
159
Citations by year
2026: 161 · 2025: 218 · 2024: 309 · 2023: 281 · 2022: 272 · 2021: 288 · 2020: 226 · 2019: 148 · 2018: 120 · 2017: 81 · 2016: 60 · 2015: 21
FWCI
7.37
Type
journal article
Language
en
Open access
closed
Locations
  • Molecular Neurobiology (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Natural Science Foundation of China
  • National Key Research and Development Program of China
Topics
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Life Sciences › Neuroscience › Neurology › Neurological Disease Mechanisms and Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
Keywords
microglia, M1 macrophage phenotype, M2 phenotype, neuroinflammation, neurodegenerative diseases, Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis, microglial polarization, amyloid plaques, tau oligomers, alpha-synuclein aggregation, neuroprotection, disease stage
MeSH terms
Animals, Humans, Phenotype, Microglia, Neurodegenerative Diseases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review